Zhang W H
Dept. Gynecologic Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
Zhonghua Zhong Liu Za Zhi. 1991 Sep;13(5):378-80.
37 patients with malignant mesodermal mixed tumor of the uterus treated from 1958 to 1987 were reviewed. It accounted for 38.5% of all uterine sarcomas during the same period. Six were homologous and 31 were heterologous in origin. The mean age was 56.8 years. 75.5% of the patients were postmenopausal. Nine (24.3%) patients had previous pelvic irradiation. There were 13 Stage I, 4 Stage II, 5 Stage III, 2 Stage IV and 13 unstaged (including 11 misdiagnosed and 2 operated in other hospital) lesions as classified according to the FIGO Staging System for malignant tumors of the Endometrium and Cervix. Twenty-six patients were treated by combined surgery and radiotherapy or chemotherapy and radiotherapy, 5 by radiotherapy alone and 6 by surgery alone. The overall 2-year survival rate was 35.1%. Twenty-two (59.5%) patients developed recurrence and/or metastasis and 86.4% (19/22) did so within 2 years after treatment. The most significant prognostic factors were: the depth of myometrial invasion, extent of lesion and method of treatment. The best 2-year survival rate (83.3%) was seen in patients treated by the combined use of surgery, radiotherapy and chemotherapy which is considered the treatment of choice for this malignancy.
对1958年至1987年期间收治的37例子宫恶性中胚叶混合瘤患者进行了回顾性研究。该肿瘤占同期所有子宫肉瘤的38.5%。其中6例为同源性，31例为异源性。平均年龄为56.8岁。75.5%的患者处于绝经后状态。9例（24.3%）患者既往接受过盆腔放疗。根据国际妇产科联盟（FIGO）子宫内膜和宫颈癌恶性肿瘤分期系统，有13例为Ⅰ期，4例为Ⅱ期，5例为Ⅲ期，2例为Ⅳ期，13例未分期（包括11例误诊和2例在其他医院手术的病例）。26例患者接受了手术联合放疗或化疗及放疗，5例仅接受放疗，6例仅接受手术。总体2年生存率为35.1%。22例（59.5%）患者出现复发和/或转移，其中86.4%（19/22）在治疗后2年内出现。最显著的预后因素为：肌层浸润深度、病变范围和治疗方法。接受手术、放疗和化疗联合治疗的患者2年生存率最高（83.3%），该联合治疗被认为是这种恶性肿瘤的首选治疗方法。
